Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)
21.88
+0.34 (1.58%)
Feb 3, 2026, 3:00 PM CST
SHA:600285 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,780 | 3,498 | 3,307 | 2,998 | 2,690 | 2,328 |
Other Revenue | 2.73 | 2.73 | 3.98 | 3.44 | 3.48 | 3.44 |
| 3,783 | 3,501 | 3,311 | 3,002 | 2,694 | 2,332 | |
Revenue Growth (YoY) | 6.15% | 5.72% | 10.31% | 11.45% | 15.52% | 8.09% |
Cost of Revenue | 735.96 | 848.37 | 888.53 | 837.53 | 707.97 | 547.68 |
Gross Profit | 3,047 | 2,652 | 2,423 | 2,164 | 1,986 | 1,784 |
Selling, General & Admin | 2,030 | 1,762 | 1,675 | 1,608 | 1,483 | 1,342 |
Research & Development | 161.64 | 131.53 | 109.65 | 125.07 | 86.21 | 97.76 |
Other Operating Expenses | 39.64 | 29.69 | 44.84 | 40.54 | 37.4 | 28.4 |
Operating Expenses | 2,236 | 1,929 | 1,834 | 1,775 | 1,609 | 1,468 |
Operating Income | 810.8 | 723.74 | 588.93 | 389.07 | 376.45 | 316.2 |
Interest Expense | -3.02 | -0.26 | -0.2 | -1.14 | -1.9 | -1.1 |
Interest & Investment Income | 60.74 | 59.04 | 55.87 | 86.61 | 43.03 | 57.89 |
Currency Exchange Gain (Loss) | -0 | -0 | -0.01 | 0 | -0 | 0 |
Other Non Operating Income (Expenses) | -2.44 | -0.18 | -1.69 | -1.75 | -1.7 | 7.08 |
EBT Excluding Unusual Items | 866.08 | 782.35 | 642.9 | 472.79 | 415.88 | 380.07 |
Impairment of Goodwill | - | - | - | - | - | -0.5 |
Gain (Loss) on Sale of Investments | 4.44 | -0.01 | 0.12 | 5.93 | 0.05 | -0.05 |
Gain (Loss) on Sale of Assets | 0.69 | -3.9 | -0.63 | -0.1 | -20.32 | -2.95 |
Asset Writedown | 0.35 | - | -1.83 | - | - | -27.8 |
Other Unusual Items | 48.47 | 49.13 | 12.49 | 38.42 | 17.74 | 15.43 |
Pretax Income | 920.03 | 827.57 | 653.04 | 517.03 | 413.35 | 364.2 |
Income Tax Expense | 117.81 | 104.99 | 84.93 | 51.73 | 50.85 | 39.82 |
Earnings From Continuing Operations | 802.21 | 722.58 | 568.12 | 465.3 | 362.5 | 324.38 |
Minority Interest in Earnings | -2.6 | -0.03 | -0.01 | -0 | -0.96 | 1.11 |
Net Income | 799.61 | 722.55 | 568.11 | 465.3 | 361.54 | 325.49 |
Net Income to Common | 799.61 | 722.55 | 568.11 | 465.3 | 361.54 | 325.49 |
Net Income Growth | 18.32% | 27.18% | 22.09% | 28.70% | 11.08% | 10.55% |
Shares Outstanding (Basic) | 566 | 561 | 561 | 557 | 556 | 568 |
Shares Outstanding (Diluted) | 570 | 564 | 566 | 568 | 567 | 568 |
Shares Change (YoY) | 1.46% | -0.42% | -0.30% | 0.26% | -0.24% | -1.22% |
EPS (Basic) | 1.41 | 1.29 | 1.01 | 0.84 | 0.65 | 0.57 |
EPS (Diluted) | 1.40 | 1.28 | 1.00 | 0.82 | 0.64 | 0.57 |
EPS Growth | 16.62% | 27.72% | 22.47% | 28.37% | 11.34% | 11.91% |
Free Cash Flow | 896.48 | 760.75 | 792.23 | 807.92 | 768.78 | 378.71 |
Free Cash Flow Per Share | 1.57 | 1.35 | 1.40 | 1.42 | 1.36 | 0.67 |
Dividend Per Share | 0.900 | 0.900 | 0.800 | 0.600 | 0.500 | 0.400 |
Dividend Growth | 12.50% | 12.50% | 33.33% | 20.00% | 25.00% | 33.33% |
Gross Margin | 80.55% | 75.77% | 73.17% | 72.10% | 73.72% | 76.51% |
Operating Margin | 21.43% | 20.67% | 17.78% | 12.96% | 13.98% | 13.56% |
Profit Margin | 21.14% | 20.64% | 17.16% | 15.50% | 13.42% | 13.96% |
Free Cash Flow Margin | 23.70% | 21.73% | 23.92% | 26.91% | 28.54% | 16.24% |
EBITDA | 879.48 | 795.48 | 664.74 | 463.4 | 447.63 | 384.66 |
EBITDA Margin | 23.25% | 22.72% | 20.07% | 15.44% | 16.62% | 16.50% |
D&A For EBITDA | 68.68 | 71.74 | 75.81 | 74.33 | 71.18 | 68.46 |
EBIT | 810.8 | 723.74 | 588.93 | 389.07 | 376.45 | 316.2 |
EBIT Margin | 21.43% | 20.67% | 17.78% | 12.96% | 13.98% | 13.56% |
Effective Tax Rate | 12.80% | 12.69% | 13.00% | 10.01% | 12.30% | 10.93% |
Revenue as Reported | 3,783 | 3,501 | 3,311 | 3,002 | 2,694 | 2,332 |
Advertising Expenses | - | 290.05 | 265.07 | 295.91 | - | 356.56 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.